HMO Research Network CERT III

描述(由申请人提供)：保健组织研究网络CERT对治疗的使用、安全性和有效性提供了重要的见解，并请求提供资金，以继续利用来自不同健康计划合作的人口作为治疗证据的普遍来源，并作为传播和实施治疗最佳做法的工具。我们的子主题将是上市后的安全，尽管我们也将继续积极促进医生和患者行为的改变，信息技术的使用，以及优化治疗方法使用的健康政策。HMORN CERT的核心将由HMO研究网络的13个健康计划组成，总会员人数为1100万。所有这些都有与其计划的高级领导和交付系统紧密联系的公共领域研究单位。HMORN CERT将使用虚拟数据仓库来促进登记、药房、诊断和程序数据的使用，这将提供最高水平的患者隐私，同时促进复杂的多点研究。所有网站也都在实施电子病历，以便进行更广泛的研究。CERT将侧重于需要详细数据和/或吸引提供者和计划成员参与的能力的研究。它还将为正在进行的Decision(AHRQ)和FDA合同提供关键的基础设施支持，并与NCI资助的HMORN癌症研究网络和NIH资助的临床转化科学中心合作。新的核心研究将包括实质性和方法学工作：1)药物洗脱冠状动脉支架的安全性和有效性的纵向研究；2)利用常规收集的电子健康数据测试快速前瞻性药物安全性评估的新方法；3)抗精神病药物在儿童中的使用和安全性，重点是血糖控制的异常；以及4)使用新的生物制剂治疗老年人类风湿性关节炎的严重感染风险。这些活动将得到其他活动的补充，包括与其他CERT的有针对性的合作。新的活动将包括：1)公共健康健康计划联盟，涉及更大的健康计划，进行需要数千万人口的药物/疫苗安全性研究；2)影响联邦医疗保险和医疗补助人口的研究；3)临床和经济审查研究所，通过为合理的覆盖决定提供信息，促进成本效益疗法的传播；以及4)教育和传播计划。

DESCRIPTION (Provided by the Applicant): The HMO Research Network CERT has provided important insights into the use, safety and effectiveness of therapies and requests funding to continue leveraging populations from a collaboration of diverse health plans as generalizable sources of therapeutics evidence and as vehicles for disseminating and implementing therapeutics best practices. Our sub-theme will be post-marketing safety, although we will also continue to be active in promoting physician and patient behavior change, the uses of information technology, and health policy to optimize the use of therapeutics. The HMORN CERT's core will consist of 13 health plans of the HMO Research Network, with total membership of 11 million. All have public domain research units strongly linked to their plans' senior leadership and delivery systems. The HMORN CERT will use a Virtual Data Warehouse to facilitate use of enrollment, pharmacy, diagnosis and procedure data, which provides the highest level of patient privacy while facilitating complex multi-site studies. All sites are also implementing electronic medical records, allowing a greater range of studies. The CERT will focus on studies requiring detailed data and/or the ability to engage providers and plan members. It will also provide critical infrastructure support for ongoing DEcIDE (AHRQ) and FDA contracts, and collaborate with the NCI-funded HMORN Cancer Research Network and NIH-funded Clinical Translational Science Centers. New core studies will include both substantive and methodological work: 1) longitudinal study of the safety and efficacy of drug-eluting coronary artery stents; 2) testing new methods for rapid prospective drug safety assessment by using routinely collected electronic health data; 3) use and safety of antipsychotic medications in children, focusing on abnormalities of glycemic control, and 4) risk of serious infection with use of new biological agents for rheumatoid arthritis in the elderly. These will be complemented by additional activities, including targeted collaborations with other CERTs. New activities will include: 1) A Health Plan Consortium for Public Health, involving larger health plans, to perform drug/vaccine safety studies requiring populations of tens of millions; 2) Studies impacting Medicare & Medicaid populations; 3) An Institute for Clinical and Economic Review to facilitate dissemination of cost effective therapies by informing rational coverage decisions; and 4) Education and dissemination programs.